| Identification | Back Directory | [Name]
9-L-Leucine-1-9-kallidin | [CAS]
71800-37-8 | [Synonyms]
(DES-ARG10,LEU9)-KALLIDIN
1-9-Kallidin, 9-L-leucine-
LYS-(DES-ARG9,LEU8)-BRADYKININ
[LYS0, DES-ARG9, LEU8]BRADYKININ
LYS-ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU
H-LYS-ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU-OH
LYS-ARG-PRO-PRO-GLY-PHE-SER-PRO-LEU: KRPPGFSPL
Lys-(Des-Arg9,Leu8)-Bradykinin
(Des-Arg10,Leu9)-Kallidin
Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt
Lys-(Des-Arg9,Leu8)-Bradykinin trifluoroacetate salt H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu-OH trifluoroacetate salt | [Molecular Formula]
C47H75N13O11 | [MDL Number]
MFCD00274007 | [MOL File]
71800-37-8.mol | [Molecular Weight]
998.2 |
| Hazard Information | Back Directory | [Description]
Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt is a peptide chain containing nine amino acids. The amino acid sequence of bradykinin is Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (RPPGFSPFR). Bradykinin is a peptide that causes blood vessels to dilate, thus resulting in lower blood pressure. A class of drugs used to lower blood pressure called ACE inhibitors lower blood pressure by increasing the concentration of bradykinin (by inhibiting its degradation). Bradykinin acts on blood vessels by releasing prostacyclin, nitric oxide, and endothelial-derived hyperpolarizing factors. | [Application]
As one of the end effectors of the kallikrein-kinin system,Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt has various biological activities, such as vasodilator, increase vascular permeability, induce contraction of non-vascular smooth muscle and so on. | [Mechanism of action]
Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt is a potent endothelium-dependent vasodilator that causes non-vascular smooth muscle contraction, increases vascular permeability and is also involved in pain mechanisms. Bradykinin also causes an increase in urine sodium, which helps lower blood pressure. It increases calcium levels inside neocortical astrocytes, causing them to release glutamate. In some patients treated with angiotensin I-converting enzyme (ACE) inhibitors, bradykinin has been implicated as a cause of dry cough. This difficult-to-treat cough usually results from discontinuation of ACE inhibitor therapy. In such cases, angiotensin II receptor antagonists are used as the next step in therapy. |
|
|